EMPEROR-Reduced
2020
Empagliflozin Outcome Trial in Chronic Heart Failure With Reduced EF
In 3,730 patients with HFrEF (EF ≤ 40 %), empagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.
Result
Efficacy: CV death or HF hospitalisationHR 0.75
Below 1 favours empagliflozin, above 1 favours placebo.
- Absolute difference
- 5.3 points
The absolute difference is derived from the event rates.
Also reported: Slower decline in renal function.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Packer M, et al. N Engl J Med. 2020;383(15):1413-1424.doi 10.1056/NEJMoa2022190
Discussion & critique
Confirmed the SGLT2-inhibitor class effect alongside DAPA-HF. No clear mortality signal individually; the pooled HFrEF data show consistent benefit.